Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.58 |
| ▸ | CALCR | P30988 | 4/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 5/20 | 0.54 |
| ▸ | NPY4R | P50391 | 5/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.54 |
| ▸ | NPY1R | P25929 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30598184 | 1.00 | OPRD1 (0.58) | OPRD1CALCRIL23RMAPK8MAPK9 | |
| SCHEMBL29706167 | 0.97 | MAPK8 (0.56) | OPRD1CALCRIL23RMAPK8MAPK9 | |
| SCHEMBL29706178 | 0.97 | MAPK8 (0.56) | OPRD1CALCRIL23RMAPK8MAPK9 | |
| SCHEMBL29706257 | 0.97 | MAPK8 (0.57) | OPRD1CALCRIL23RMAPK8MAPK9 | |
| SCHEMBL29706321 | 0.96 | MAPK8 (0.55) | OPRD1CALCRIL23RMAPK8MAPK9 | |
| SCHEMBL30688075 | 0.96 | MAPK8 (0.60) | OPRD1CALCRMAPK8MAPK9MAPK10 | |
| SCHEMBL29706327 | 0.96 | MAPK8 (0.55) | OPRD1CALCRIL23RMAPK8MAPK9 | |
| SCHEMBL29706150 | 0.96 | MAPK8 (0.55) | OPRD1CALCRIL23RMAPK8MAPK9 | |
| SCHEMBL29706239 | 0.95 | MAPK8 (0.59) | OPRD1CALCRMAPK8MAPK9MAPK10 | |
| SCHEMBL30688076 | 0.95 | MAPK8 (0.59) | OPRD1CALCRMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416329-A1 | A PEPTIDE WITH DISULFIDE BONDS AND INHIBITORY ACTIVITY AGAINST SERINE PROTEASES, DERIVED HYBRID PEPTIDES THEREOF, AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-12-28 | — | — | US | disclosed |
| CN-116615436-A | Disulfide bond-containing polypeptide with serine protease activity inhibiting function, hybrid peptide derived from disulfide bond-containing polypeptide and application of disulfide bond-containing polypeptide | 中国医学科学院药物研究所 | 2023-08-18 | — | — | CN | disclosed |
| WO-2022111713-A9 | POLYPEPTIDE CONTAINING DISULFIDE BONDS AND CAPABLE OF INHIBITING ACTIVITY OF SERINE PROTEASE, DERIVED HYBRID PEPTIDE THEREOF, AND USE THEREOF | 中国医学科学院药物研究所 | 2023-07-27 | — | — | WO | disclosed |
| CN-114573686-A | Polypeptide containing disulfide bond and having serine protease activity inhibition function and application thereof | 中国医学科学院药物研究所 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022111713-A1 | POLYPEPTIDE CONTAINING DISULFIDE BONDS AND CAPABLE OF INHIBITING ACTIVITY OF SERINE PROTEASE, DERIVED HYBRID PEPTIDE THEREOF, AND USE THEREOF | 中国医学科学院药物研究所 | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416329-A1 | A PEPTIDE WITH DISULFIDE BONDS AND INHIBITORY ACTIVITY AGAINST SERINE PROTEASES, DERIVED HYBRID PEPTIDES THEREOF, AND USES THEREOF | VIP, SI, TMPRSS15 | OPRD1 4595/4885CALCR 2656/4885IL23R 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.